Add BrightSurf on Google Email

Neural signaling protein could be therapeutic target for autism-linked gene deletion

Researchers found that PSD-95 levels were elevated in mice with MEF2C haploinsufficiency, leading to cognitive impairments and seizures. Targeting PSD-95 may be effective in reducing seizures and rescuing cognitive abilities in those with MEF2C haploinsufficiency or other neurodevelopmental disorders.

SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateNov 4, 2026

Study reveals how congenital anomalies and deprivation impact children’s educational achievement

A new study from Swansea University found that children with major congenital anomalies were less likely to achieve national academic standards, with socioeconomic deprivation having a more pronounced impact. The researchers highlight the need for integrated provision across health, education, and social services to support children wi...

SourceSwansea University·JournalPLOS Medicine·TypeData/statistical analysis·DateNov 3, 2026

“Average” human genome described for first time, with implications for disease risk

The study analyzed data from nearly 1 million individuals, revealing that everyone has around five million genetic variants, including 10,000 that alter gene sequences and 50 rare variants of uncertain clinical relevance. Most people would be categorized as at high risk of genetic risk for around three conditions, highlighting the impo...

SourceUniversity of Exeter·JournalGenome Medicine·TypeObservational study·DateOct 22, 2026

Mount Sinai to lead national trial of targeted therapy for infants with noonan syndrome and severe hypertrophic cardiomyopathy

The BabyMERIT trial will evaluate trametinib in infants with Noonan syndrome and related conditions who develop severe hypertrophic cardiomyopathy, a potentially life-threatening condition. The study aims to improve outcomes for these young patients by targeting a molecular pathway known to drive these disorders.

New gene-editing technology brings genetic diseases closer to treatment

Researchers at Aarhus University have demonstrated a new form of gene therapy that can correct genetic defects in patients' own stem cells. The technique, called prime editing, builds on CRISPR technology but works in a different way, inserting a small piece of correct DNA at the precise location of the defect. This method has signific...

SourceAarhus University·JournalScience Translational Medicine·TypeExperimental study·DateOct 13, 2026

Children’s Hospital of Philadelphia researchers identify role of newly discovered genetic variant in neurodevelopmental disorder

Researchers at Children's Hospital of Philadelphia identified a genetic variant in the MAP2K4 gene associated with neurodevelopmental disorder symptoms such as developmental delay and epilepsy. The study revealed impaired JNK signaling in induced pluripotent stem cell-derived neurons, providing a potential therapeutic target for furthe...

SourceChildren's Hospital of Philadelphia·JournalAmerican Journal of Human Genetics·TypeExperimental study·DateOct 13, 2026

Unexpected link identified between rare metabolic disease gene and inherited blindness

An international study found that variants in the IDUA gene, associated with mucopolysaccharidosis type I, can cause inherited retinal disease without broader health problems. The study highlights the importance of understanding how genetic variants affect the body, potentially leading to earlier recognition and treatment opportunities.

SourceGreenwood Genetic Center·JournalAmerican Journal of Human Genetics·TypeExperimental study·DateOct 6, 2026

New clues to how lymphatic malformations develop

A study by the University of Osaka has identified shared disease mechanisms in lymphatic malformations, including the PI3K/AKT/mTOR pathway, and found that sirolimus, a drug targeting this pathway, is clinically effective across patients. The research also uncovered 10 additional disease-related molecules, including NFATC1, which may r...

SourceThe University of Osaka·JournalLaboratory Investigation·TypeExperimental study·DateOct 5, 2026

Wiskott-Aldrich Syndrome: Long-term results of gene therapy developed at the San Raffaele-Telethon Institute published in the New England Journal of Medicine

A novel autologous gene therapy for Wiskott-Aldrich syndrome has demonstrated durable clinical benefits in a phase 3 study, with 96% survival at 1 and 5 years. The treatment, etu-cel, has also reduced severe infections and moderate-to-severe bleeding events.

SourceFondazione Telethon·TypeRandomized controlled/clinical trial·DateSep 24, 2026

Earlier HCT improves survival for youth with Shwachman-Diamond Syndrome

A multi-center international study published in NEJM found that performing hematopoietic cell transplants shortly after detecting high-risk features in patients with Shwachman-Diamond Syndrome significantly improves survival rates. The study analyzed 847 cases and found that survival appeared to improve when early HCT treatment occurre...

SourceCincinnati Children's Hospital Medical Center·JournalNew England Journal of Medicine·TypeMeta-analysis·DateSep 23, 2026

Modeling childhood epilepsy in brain organoids points to possible treatments

A new study by UC Berkeley researchers suggests that hyperreactive astrocytes are a primary driver of childhood epilepsy, particularly in the inherited disorder tuberous sclerosis complex. The findings highlight possible therapies to reduce inflammation and alleviate seizures, challenging the traditional view that neurons are the sole ...

SourceUniversity of California - Berkeley·JournalNature·TypeExperimental study·DateSep 23, 2026

Incremental progress on a stubborn medical mystery: New studies yield insight on the signs and causes of hypermobile Ehlers-Danlos Syndrome

Researchers have made incremental progress in understanding hypermobile Ehlers-Danlos Syndrome, a genetic disorder characterized by unstable joints and chronic pain. Studies have revealed correlations between hormone levels and symptom severity, as well as the relationship between hypermobile individuals and sleep apnea.

New hereditary retinal disease discovered

Researchers identified a previously unrecognized form of inherited retinal degeneration caused by a specific EFEMP1 gene variant, primarily affecting peripheral retina and rod photoreceptors. The disease can begin before visible retinal damage and may go undetected for a considerable period due to relatively preserved central vision.

SourceUniversitatsklinikum Bonn·JournalJAMA Ophthalmology·DateSep 10, 2026

RNA breakthrough provides hope for thousands of untreatable diseases

Researchers at the University of Toronto have developed a next-generation RNA therapeutic approach that can treat a wide range of genetic diseases by helping cells read through premature stop signals. The approach, centered on transfer RNA, has shown promise in laboratory and preclinical models of cystic fibrosis, and may be combined w...

SourceUniversity of Toronto - Leslie Dan Faculty of Pharmacy·JournalScience·TypeExperimental study·DateAug 27, 2026

Chinese Medical Journal review highlights new directions in pulmonary arterial hypertension

A new review highlights how molecular biology advances are reframing PAH as a complex vascular remodeling disease driven by endothelial dysfunction, chronic inflammation, metabolic dysregulation, and genetic susceptibility. Emerging therapies target the BMP/TGF-β pathway, growth factor signaling, and inflammatory pathways.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateAug 11, 2026

Children's Hospital Colorado helps shape national standards for neurodevelopmental and neurocognitive care in sickle cell disease

New national standards recommend earlier screening and lifelong monitoring for development and cognition in individuals with SCD, aiming to reduce variability in care. The guidance, developed in collaboration with Children's Colorado, provides a tiered approach to care, including surveillance and evaluation.

SourceChildren's Hospital Colorado·JournalPediatric Blood & Cancer·DateJul 28, 2026

Crnic Institute landmark research paves the way for personalized medicine in Down syndrome

Researchers at the University of Colorado Anschutz Linda Crnic Institute discovered unique biological processes altered among individuals with Down syndrome who have different sets of co-occurring conditions. The findings mark an important step toward personalized treatment, enabling future targeted therapies and improved health outcomes.

SourceUniversity of Colorado Anschutz·JournalNature Communications·DateJul 23, 2026

Gene therapy reverses Fragile X deficits in mice

Researchers developed a gene therapy that restored normal brain activity and improved behavior in mice with Fragile X syndrome by replacing the missing FMRP protein. The treatment administered during early development showed significant improvements in cognitive flexibility, social interactions, and probabilistic reversal learning.

SourceUniversity of California - Riverside·JournalMolecular Therapy — Nucleic Acids·TypeExperimental study·DateJun 18, 2026

Large-scale population studies needed to reduce risks from newborn genome screening

Researchers emphasize the need for large-scale population studies to assess the risks of newborn genome screening and minimize overdiagnosis. The study highlights that most genetic research has been conducted in individuals with a condition or high-risk family, resulting in underestimated risk estimates.

SourceUniversity of Exeter·JournalEuropean Journal of Human Genetics·TypeObservational study·DateJun 15, 2026

Completeness, accuracy nearly doubled for Japanese genome mapping

A team of researchers has made a significant contribution to understanding human genetics by mapping the Japanese genome, revealing new insights into genetic disease shaping in the Japanese population. The study nearly doubled the complete reconstruction rate to 91.2%, enabling better personalized medicine and treatment options.

SourceResearch Organization of Information and Systems·JournalNature Communications·TypeData/statistical analysis·DateJun 9, 2026

Alliance digital tool proves effective at keeping patients engaged in trials

A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.

SourceAlliance for Clinical Trials in Oncology·JournalJNCI Cancer Spectrum·TypeSurvey·DateJun 8, 2026